Navigation Links
Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Date:5/25/2011

RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor (TKI). Researchers observed a tumor size reduction of up to 76 percent over a treatment period of up to five months.(1) The most common drug-related adverse events were rash and diarrhea, with three patients (11.5%) experiencing Grade 3 rash. Afatinib is an orally-administered irreversible inhibitor of the erbB family of receptor tyrosine kinases, specifically EGFR and HER2.  It is in late-stage development in advanced NSCLC and breast cancer.

Boehringer Ingelheim and QIAGEN are pleased that ASCO and the National Comprehensive Cancer Network (NCCN), two leading oncology organizations, recently recommended EGFR mutation testing for patients with metastatic or recurrent NSCLC.  These recommendations underscore the importance of genetic tumor testing to predict patient response to certain treatments, enabling personalized healthcare.  Boehringer Ingelheim has partnered with QIAGEN to develop a real-time polymerase chain reaction assay (real-time PCR) companion diagnostic test for afatinib that, if approved, could help physicians identify which patients may benefit from EGFR-targeted therapies.

"The ASCO and NCCN EGFR mutation testing recommendations reinforce the importance of identifying the appropriate NSCLC patients for clinical trials," said Christopher Corsico, M.D., M.P.H., Senior Vice President, Medicine and Regulatory, Boehringer Ingelheim Pharmaceuticals, Inc. "
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... HORSHAM, Pa., Sept. 20, 2011 Verilogue, the ... upcoming presentations highlighting company initiatives, including CareCoach.com, the ... healthcare dialogue between patients, caregivers and their physicians. ... conferences in September: e-Patient Connections; ...
... Sept. 20, 2011 Reportlinker.com announces that a ... catalogue: Rheumatoid Arthritis Market Forecast ... The launch of novel oral drugs and reformulations ... across the seven major markets, rising from $12bn ...
Cached Medicine Technology:Verilogue to Present at Upcoming Health IT and Patient-Focused Conferences 2Rheumatoid Arthritis Market Forecast 2
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids ... are now being treated at Florida Hospital Tampa with the device that provides ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Awarded to only ... is proud to announce that they are the latest recipients of the Center ... status as one of the worldwide leaders in the science of hair transplant. , ...
(Date:7/31/2015)... La Mirada, CA (PRWEB) , ... July 31, ... ... in Southern California, has announced plans to release a newly redesigned website at ... easier navigation and enhanced user experience. , The redesign serves to provide ...
(Date:7/31/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... July 31, ... ... the 100th baby at Beaumont Hospital's Karmanos Center for Natural Birth . ... expectant mothers looking for a safe natural childbirth experience. With nurses and caregivers ...
(Date:7/31/2015)... ... July 31, 2015 , ... A family-run business ... oils from ingredients sourced all over the world, then manufactured into specific formulations ... have developed the highest-quality oils in the industry, which we are bringing to ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... PARK, Fla., May 18 Transitions Optical, Inc.,today announced ... relevant information about eye health issues through SMS text ... have the option to subscribe to,receive valuable advice and ... eyes to see better today and in the future. ...
... Washinton DC (18 May 2009) Research published this week ... the annual costs of autism spectrum disorder (ASD) to be ... children with ASDs were estimated to be 2.7 billion per ... be presented at the Autism & Employment Workshop taking place ...
... MEI,s Broad Solution Offerings CORAL SPRINGS, Fla., May ... of The MEI Healthcare Group, announced today a ... GE ), a leading provider of healthcare technology. ... customers the option of MEI,s broad solutions, including ...
... by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) ... Lost Their Jobs in 2009PHILADELPHIA, May 18 Shire ... global specialty biopharmaceutical company, is responding to the needs ... and prescribed gastrointestinal (GI) medications from Shire by expanding ...
... season; experts less sure about global outlook , , MONDAY, May ... raising critical questions about the timing of bringing a new ... the people who need it. , If vaccine manufacturers shift ... seasonal influenza vaccine, experts say. If they wait too long, ...
... blast injuries have become the signature injuries. These can ... damage to the visual system and the visual processing centers ... with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, on ... N.Y., May 18 The journey home is a bittersweet ...
Cached Medicine News:Health News:SMS Technology Places Eye Health Educational Information at Hispanics' Fingertips 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 3Health News:MEI Development Corporation and GE Healthcare Sign Strategic Agreement 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 3Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 4Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 5Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2
... needed for quality, comprehensive portable and bedside ... allows you to see up to four ... touch screen allows easy navigation through menus ... temperature., ,Standard features include two channels ...
... all-in-one anesthesia monitor., ,The Cardiocap/5 ... for use in the operating room, ... PACU. The Cardiocap/5 offers full vital ... of oxygenation and circulation to advanced ...
... tool for Clinical Professionals and Researchers., ,S/5 ... easy and efficient way to collect data from ... to days at selectable time intervals. With S/5 ... from the monitor via an interface cable or ...
... for intermediate care., ,The S/5 FM is ... S/5 product line., ,The S/5 FM has ... to grow. The new Patient Side Module (PSM) ... up to 12-lead ECG, NIBP, motion-tolerant SpO 2 ...
Medicine Products: